Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid …
S Ramiro, A Sepriano, K Chatzidionysiou… - Annals of the …, 2017 - ard.bmj.com
Objectives To assess the safety of synthetic (s) and biological (b) disease-modifying
antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform …
antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform …
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid …
S Ramiro, C Gaujoux-Viala, JL Nam… - Annals of the …, 2014 - ard.bmj.com
Objectives To update the evidence for the safety of synthetic disease-modifying
antirheumatic drugs (sDMARDs), glucocorticoids (GC) and biological DMARDs (bDMARDs) …
antirheumatic drugs (sDMARDs), glucocorticoids (GC) and biological DMARDs (bDMARDs) …
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)
SM Langan, SAJ Schmidt, K Wing, V Ehrenstein… - bmj, 2018 - bmj.com
In pharmacoepidemiology, routinely collected data from electronic health records (including
primary care databases, registries, and administrative healthcare claims) are a resource for …
primary care databases, registries, and administrative healthcare claims) are a resource for …
Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years' experience at a single centre
MY Md Yusof, A Kabia, M Darby, G Lettieri… - …, 2017 - academic.oup.com
Objective. To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial
lung disease (RA-ILD) and identify factors associated with outcome after treatment. Methods …
lung disease (RA-ILD) and identify factors associated with outcome after treatment. Methods …
Relation of completeness of reporting of health research to journals' endorsement of reporting guidelines: systematic review
Objective To assess whether the completeness of reporting of health research is related to
journals' endorsement of reporting guidelines. Design Systematic review. Data sources …
journals' endorsement of reporting guidelines. Design Systematic review. Data sources …
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses
Introduction Infection is a major cause of morbidity and mortality in patients with rheumatoid
arthritis (RA). The objective of this study was to perform a systematic review and meta …
arthritis (RA). The objective of this study was to perform a systematic review and meta …
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)
F Costantino, L Carmona, M Boers… - Annals of the …, 2021 - ard.bmj.com
Objective To produce European League Against Rheumatism (EULAR) recommendations
for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs) …
for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs) …
Biologics registers in RA: methodological aspects, current role and future applications
E Nikiphorou, MH Buch, KL Hyrich - Nature Reviews Rheumatology, 2017 - nature.com
The beginning of the 21st century saw a biopharmaceutical revolution in the treatment of
inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of …
inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of …
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries …
B Michelsen, U Lindström, C Codreanu, A Ciurea… - RMD open, 2020 - rmdopen.bmj.com
Objectives To explore 6-month and 12-month secukinumab effectiveness in patients with
axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous …
axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous …
Real‐World Six‐and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European …
B Michelsen, S Georgiadis, D Di Giuseppe… - Arthritis care & …, 2022 - Wiley Online Library
Objective There is a lack of real‐life studies on interleukin‐17 (IL‐17) inhibition in psoriatic
arthritis (PsA). We assessed real‐life 6‐and 12‐month effectiveness (ie, retention, remission …
arthritis (PsA). We assessed real‐life 6‐and 12‐month effectiveness (ie, retention, remission …